{"id":"ethinyl-estradiol-norelgestromin-transdermal-contraceptive","safety":{"commonSideEffects":[{"rate":null,"effect":"Breast tenderness"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Application site reaction"},{"rate":null,"effect":"Breakthrough bleeding"},{"rate":null,"effect":"Venous thromboembolism"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The combination of an estrogen (ethinyl estradiol) and a progestin (norelgestromin) works synergistically to prevent conception through multiple mechanisms: suppression of the hypothalamic-pituitary-ovarian axis to prevent ovulation, increased cervical mucus viscosity to impede sperm transport, and alterations to the endometrium. Delivered transdermally, the patch provides steady-state hormone levels with improved compliance compared to oral formulations.","oneSentence":"Ethinyl estradiol and norelgestromin suppress ovulation by inhibiting the luteinizing hormone surge and thickening cervical mucus, preventing pregnancy.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:45:57.734Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of pregnancy in women of childbearing age"}]},"trialDetails":[{"nctId":"NCT07083635","phase":"PHASE2","title":"Transdermal Ethinyl Estradiol and Norelgestromin for Irregular Bleeding in Contraceptive Implant Users","status":"RECRUITING","sponsor":"Chulalongkorn University","startDate":"2025-07-29","conditions":"Menstruation Disturbances, Metrorrhagia, Uterine Hemorrhage","enrollment":40},{"nctId":"NCT05139121","phase":"PHASE3","title":"Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles","status":"COMPLETED","sponsor":"Mylan Technologies Inc.","startDate":"2021-10-26","conditions":"Contraception","enrollment":1319},{"nctId":"NCT04423068","phase":"EARLY_PHASE1","title":"Inpatient Adolescent Contraception","status":"COMPLETED","sponsor":"Children's Mercy Hospital Kansas City","startDate":"2020-12-10","conditions":"Pregnancy Related, Contraception, Contraceptive Usage","enrollment":25},{"nctId":"NCT00125983","phase":"PHASE2","title":"Drug Interactions Between Lopinavir/Ritonavir and Oral or Patch Contraceptives in HIV Infected Women","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Pregnancy","enrollment":32},{"nctId":"NCT02367833","phase":"PHASE4","title":"Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis","status":"COMPLETED","sponsor":"Penn State University","startDate":"2015-01","conditions":"Bone; Disorder, Development and Growth","enrollment":60},{"nctId":"NCT00377988","phase":"","title":"A Postmarketing Study of the Risk of Venous Thromboembolism (Blood Clots), Myocardial Infarction (Heart Attacks), and Stroke Among Women Using ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared With Women Who Take Oral Contraceptives for Birth Control","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2002-04","conditions":"Contraception, Female Contraception","enrollment":423},{"nctId":"NCT00331071","phase":"","title":"Postmarketing Study of ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) in Relation to Venous Thromboembolism (Blood Clots), Stroke and Heart Attacks","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2002-04","conditions":"Contraception, Female Contraception","enrollment":334},{"nctId":"NCT00511784","phase":"","title":"Relative Risks for Non-fatal Venous Thromboembolism, Ischemic Stroke and Myocardial Infarction in Users of ORTHO EVRA(Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared to Levonorgestrel-containing Oral Contraceptives.","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2006-11","conditions":"Contraception, Female Contraception, Fertility Control","enrollment":440},{"nctId":"NCT00984789","phase":"PHASE3","title":"Birth Control Patch Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-05","conditions":"Contraception","enrollment":393},{"nctId":"NCT01535820","phase":"PHASE1","title":"The Effect of an Adhesive Overlay on the Delivery of Contraceptive Hormones From ORTHO EVRA® in Healthy Women","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2011-03","conditions":"Healthy Volunteers","enrollment":54},{"nctId":"NCT00258076","phase":"PHASE1","title":"A Study to Evaluate the Hormone Exposure From Multiple Commercial Lots of ORTHO EVRA (a Transdermal Contraceptive Patch)","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2004-04","conditions":"Contraception, Female Contraception","enrollment":53},{"nctId":"NCT01087879","phase":"NA","title":"The Effect of Hormonal Contraceptives on Androgens and Glucose Metabolism","status":"COMPLETED","sponsor":"University of Oulu","startDate":"2007-10","conditions":"Contraception","enrollment":45},{"nctId":"NCT00775086","phase":"PHASE1","title":"Bioequivalence Study of Patches With Different Equilibration Profiles","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2004-05","conditions":"Female Contraception","enrollment":42},{"nctId":"NCT00236795","phase":"PHASE3","title":"A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Triphasil.","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"1997-01","conditions":"Contraception, Female Contraception","enrollment":1494},{"nctId":"NCT00236782","phase":"PHASE3","title":"A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Mercilon.","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"1997-10","conditions":"Contraception","enrollment":1517},{"nctId":"NCT00258063","phase":"PHASE1","title":"A Study to Evaluate the Exposure of Norelgestromin and Ethinyl Estradiol From Commercial Lots of EVRA (a Transdermal Contraceptive Patch Manufactured by LOHMANN Therapie-Systeme) and CILEST (an Oral Contraceptive)","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2004-05","conditions":"Contraception, Female Contraception","enrollment":60},{"nctId":"NCT00697307","phase":"","title":"Bioequivalence Study of Patches With Different Release Profiles","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2003-03","conditions":"Female Contraception","enrollment":43},{"nctId":"NCT00254865","phase":"PHASE1","title":"A Comparative Pharmacokinetic Study of ORTHO EVRA (a Transdermal Contraceptive Patch) and CILEST (an Oral Contraceptive) in Healthy Female Volunteers","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2002-08","conditions":"Contraception, Female Contraception","enrollment":34},{"nctId":"NCT00236769","phase":"PHASE3","title":"A Study of Efficacy and Safety With the Transdermal Contraceptive System.","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"1997-11","conditions":"Contraception, Female Contraception","enrollment":1751},{"nctId":"NCT00261482","phase":"PHASE4","title":"Evaluation of Women's Experience With EVRA (Norelgestromin + Ethinyl Estradiol) Transdermal Contraceptive Patch Compared With Previous Methods of Contraception.","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2003-07","conditions":"Contraception, Female Contraception","enrollment":778},{"nctId":"NCT00653016","phase":"PHASE4","title":"An Open-label, Multicentre Study on Preference and Satisfaction of Canadian Women for the Transdermal Contraceptive Patch vs. Previous Primary Contraceptive Method","status":"COMPLETED","sponsor":"Janssen-Ortho Inc., Canada","startDate":"2002-10","conditions":"Female Contraception","enrollment":405},{"nctId":"NCT00269620","phase":"PHASE4","title":"PARIS or PAtch RIng Study: A Trial to Evaluate NuvaRing Versus OrthoEvra","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2005-06","conditions":"Contraception","enrollment":500},{"nctId":"NCT00554632","phase":"NA","title":"Birth Control Pill vs Birth Control Patch Study","status":"COMPLETED","sponsor":"University of Vermont","startDate":"2003-04","conditions":"Venous Thrombosis","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":36,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["OrthoEvra"],"phase":"marketed","status":"active","brandName":"ethinyl estradiol/norelgestromin transdermal contraceptive","genericName":"ethinyl estradiol/norelgestromin transdermal contraceptive","companyName":"University of Pittsburgh","companyId":"university-of-pittsburgh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ethinyl estradiol and norelgestromin suppress ovulation by inhibiting the luteinizing hormone surge and thickening cervical mucus, preventing pregnancy. Used for Prevention of pregnancy in women of childbearing age.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}